Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has scheduled the release of its financial results and operational highlights for the second quarter of 2026 before the market opens on August 10, 2026. The company will host a conference call and webcast at 8:30 a.m. ET that same day to discuss the results. A replay of the webcast will be available in the Investors section of the company’s website following the event.
This announcement is significant as it comes shortly after the FDA approval of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years. The approval marks a major milestone for Tonix, which is now a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments for areas of high unmet medical need. Investors will be keen to hear about initial commercial traction for TONMYA and its impact on the company’s financial performance.
Tonix’s CNS portfolio extends beyond TONMYA. The company is evaluating TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder. Additionally, TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, a rare disease, is in development. On the immunology front, Tonix is advancing monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These programs address substantial unmet needs and could drive long-term value.
The company also markets acute migraine products Zembrace SymTouch and Tosymra, supported by its CNS commercial infrastructure. During the call, management may provide updates on sales trends and pipeline progress. For further details, the full press release is available at https://ibn.fm/A9CfR.
The financial results call offers a crucial opportunity for stakeholders to assess Tonix’s trajectory following its transition to a commercial-stage entity. With multiple catalysts ahead, including potential label expansions for TONMYA and clinical data readouts, the second-quarter report will be closely watched. Investors can access the latest news and updates on TNXP at https://ibn.fm/TNXP.
